US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Reminder: InDex Pharmaceuticals hosts Capital Markets Day on March 14, 2022

March 7, 2022 – InDex Pharmaceuticals Holding AB (publ) invites investors, analysts and media to a Capital Markets Day on March 14, 2022. The Capital Markets Day will be held in Krügersalen at Kapitel 8, Tändstickspalatset, Västra Trädgårdsgatan 15 in Stockholm. The presentations will start at 15.00 CET with registration from 14.30 CET.The focus of the Capital Markets Day will be on the ongoing phase III study CONCLUDE with the drug candidate cobitolimod, cobitolimod's market potential and InDex’s long-term strategies for commercialisation of cobitolimod. Cobitolimod is under development as

InDex Pharmaceuticals announces the agenda for its Capital Markets Day in Stockholm on April 25, 2018

April 12, 2018 – InDex Pharmaceuticals Holding AB (publ) (”InDex”) today announced the agenda for its Capital Markets Day that will take place in Stockholm on Wednesday April 25, 2018, for investors, analysts and media.Members of InDex’s senior management will be joined by Professor Raja Atreya from the University of Erlangen-Nürnberg, and Professor Walter Reinisch from the Medical University of Vienna. The program includes an overview of the disease ulcerative colitis, the research landscape and the company's lead drug candidate cobitolimod, as well as the ongoing phase IIb study CONDUCT.

Save the date: InDex Pharmaceuticals to host Capital Markets Day in Stockholm on April 25, 2018

March 26, 2018 – InDex Pharmaceuticals Holding AB (publ) (”InDex”) today announced that the company will host a Capital Markets Day in Stockholm on Wednesday April 25, 2018 for investors, analysts and media.The purpose of the Capital Markets Day is to provide an overview of ulcerative colitis and the drug candidate cobitolimod from a scientific and market perspective. Cobitolimod is a first-in-class Toll-like receptor 9 (TLR9) agonist under development by InDex as a novel therapy for moderate to severe ulcerative colitis. Cobitolimod is currently being evaluated in the phase II study

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe